nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.01.2016 | Infection (J Halperin, Section Editor)

Infection and Stroke: an Update on Recent Progress

verfasst von: Eliza C. Miller, Mitchell S. V. Elkind

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The role of infection in cerebrovascular disease is complex and remains incompletely understood. Over the last 5 years, investigators have made notable inroads in untangling this thorny topic. In this review, we examine these recent developments, concentrating on four aspects of the relationship between infection and stroke. We first discuss specific infectious agents as direct causes of stroke, focusing on recent work implicating herpesviruses and HIV in cerebral vasculopathy. We then discuss systemic infection of any type as a stroke trigger, focusing on the relationship of infection to timing of acute stroke, both in children and adults, as well as the role of vaccination in stroke prevention. We examine the evidence for chronic infection or “infectious burden” as a stroke risk factor. Finally, we discuss recent work on infection as a risk factor for increased morbidity after stroke, possible mechanisms mediating this effect, and the evidence for prophylactic antibiotics.

Karenberg A, Hort I. Medieval descriptions and doctrines of stroke: preliminary analysis of select sources. Part I: the struggle for terms and theories—late antiquity and early middle ages. J Hist Neurosci. 1998;7:162–73.PubMedCrossRef

Marie P. Hémiplégie cérébrale infantile et maladies infectieuses. Prog Med Paris. 1885;13:167–9.

Freud S. Die infantile Cerebrallähmung. Nothnagel H, editor. Specielle Pathologie 9, Teil 3 (I. Hälfte). Vienna, Austria: Holder; 1897. pp. 1–327.

Osler W. The principles and practice of medicine, designed for the use of practitioners and students of medicine. 7th ed. New York: D. Appleton and company; 1910.

Frothingham C. The relation between acute infectious diseases and arterial lesions. Arch Intern Med. 1911;8:153–62.CrossRef

Ophüls W. Arteriosclerosis and cardiovascular disease: their relation to infectious diseases. JAMA. 1921;76:700–1.CrossRef

Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med. 1978;148:335–40.PubMedCrossRef

Hindfelt B, Nilsson O. Brain infarction in young adults (with particular reference to pathogenesis). Acta Neurol Scand. 1977;55:145–57.PubMedCrossRef

Grindal AB, Cohen RJ, Saul RF, Taylor JR. Cerebral infarction in young adults. Stroke. 1978;9:39–42.PubMedCrossRef

10.

Chopra JS, Prabhakar S. Clinical features and risk factors in stroke in young. Acta Neurol Scand. 1979;60:289–300.PubMedCrossRef

11.

Syrjanen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J (Clin Res Ed). 1988;296:1156–60.CrossRef

12.

Finsterer J, Auer H. Parasitoses of the human central nervous system. J Helminthol. 2013;87:257–70.PubMedCrossRef

13.

Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation. 1996;94:922–7.PubMedCrossRef

14.

Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol. 1999;34:1738–43.PubMedCrossRef

15.

Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch Intern Med. 2000;160:2027–32.PubMedCrossRef

16.

Grahame-Clarke C, Chan NN, Andrew D, Ridgway GL, Betteridge DJ, Emery V, et al. Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation. 2003;108:678–83.PubMedCrossRef

17.

Sun Y, Pei W, Welte T, Wu Y, Ye S, Yang Y. Cytomegalovirus infection is associated with elevated interleukin-10 in coronary artery disease. Atherosclerosis. 2005;179:133–7.PubMedCrossRef

18.

Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20:2275–83.PubMedCrossRef

19.

Nerheim PL, Meier JL, Vasef MA, Li W-G, Hu L, Rice JB, et al. Enhanced cytomegalovirus infection in atherosclerotic human blood vessels. Am J Pathol. 2004;164:589–600.PubMedPubMedCentralCrossRef

20.

Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation. 1998;98:2796–9.PubMedCrossRef

21.

Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Stroke. 1999;30:299–305.PubMedCrossRef

22.

Borgia MC, Mandolini C, Barresi C, Battisti G, Carletti F, Capobianchi MR. Further evidence against the implication of active cytomegalovirus infection in vascular atherosclerotic diseases. Atherosclerosis. 2001;157:457–62.PubMedCrossRef

23.

Betjes MGH, Litjens NHR, Zietse R. Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. Nephrol Dial Transplant. 2007;22:3298–303.PubMedCrossRef

24.

Ozdemir FN, Akgul A, Altunoglu A, Bilgic A, Arat Z, Haberal M. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc. 2007;39:990–2.PubMedCrossRef

25.

Wolf SC, Brehm BR, Mayer O, Jurgens S, Schultze G, Risler T. Infectious risk factors for atherosclerotic vascular disease in hemodialysis patients--Chlamydia pneumoniae but not Helicobacter pylori or cytomegalovirus is associated with increased C-reactive protein. Ren Fail. 2004;26:279–87.PubMedCrossRef

26.•

Ji Y-N, An L, Zhan P, Chen X-H. Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep. 2012;39:6537–46. This systematic review and meta-analysis examined the association of CMV and coronary artery atherosclerosis, looking at 55 case–control studies (6 prospective, 49 retrospective) involving 9000 cases and 8608 controls. CMV was a clear risk factor for coronary disease; the association was even stronger (OR 8.21) in studies where PCR was used as the detection method.PubMedCrossRef

27.

Tracy RP, Doyle MF, Olson NC, Huber SA, Jenny NS, Sallam R, et al. T-helper type 1 bias in healthy people is associated with cytomegalovirus serology and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2013;2:e000117.PubMedPubMedCentralCrossRef

28.

Sacre K, Hunt PW, Hsue PY, Maidji E, Martin JN, Deeks SG, et al. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS. 2012;26:805–14.PubMedPubMedCentralCrossRef

29.

Assinger A, Kral JB, Yaiw KC, Schrottmaier WC, Kurzejamska E, Wang Y, et al. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses. Arterioscler Thromb Vasc Biol. 2014;34:801–9.PubMedCrossRef

30.•

Ponroy N, Taveira A, Mueller NJ, Millard A-L. Statins demonstrate a broad anti-cytomegalovirus activity in vitro in ganciclovir-susceptible and resistant strains. J Med Virol. 2015;87:141–53. This bench study examined the effect of statins on CMV-infected human aortic endothelial cells and fibroblasts in vitro. Atorva-, fluva-, and pravastatin, but not simvastatin, reduced CMV titers in both cell types with an efficacy comparable to ganciclovir. The effect was retained in ganciclovir-resistant strains.PubMedCrossRef

31.

Rosenblum WI, Hadfield MG, Young HF. Granulomatous angiitis with preceding varicella zoster. Ann Neurol. 1978;3:374–5.PubMedCrossRef

32.

Gilden DH, Kleinschmidt-DeMasters BK, Wellish M, Hedley-Whyte ET, Rentier B, Mahalingam R. Varicella zoster virus, a cause of waxing and waning vasculitis: the New England Journal of Medicine case 5–1995 revisited. Neurology. 1996;47:1441–6.PubMedCrossRef

33.

Nagel MA, Gilden D. Update on varicella zoster virus vasculopathy. Curr Infect Dis Rep. 2014;16:407.PubMedPubMedCentralCrossRef

34.

Nagel MA, Traktinskiy I, Azarkh Y, Kleinschmidt-DeMasters B, Hedley-Whyte T, Russman A, et al. Varicella zoster virus vasculopathy: analysis of virus-infected arteries. Neurology. 2011;77:364–70.PubMedPubMedCentralCrossRef

35.•

Nagel MA, Traktinskiy I, Stenmark KR, Frid MG, Choe A, Gilden D. Varicella-zoster virus vasculopathy: immune characteristics of virus-infected arteries. Neurology. 2013;80:62–8. This study examined pathological changes in VZV-infected cerebral and temporal arteries at various stages of infection, and compared with control normal arteries. Inflammatory cells and viral antigen were found in abundance in the adventitia of VZV-infected arteries only, along with thickened intima, supporting a role for viral-induced inflammation in arterial wall remodeling.PubMedPubMedCentralCrossRef

36.

Nagel MA, Forghani B, Mahalingam R, Wellish MC, Cohrs RJ, Russman AN, et al. The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology. 2007;68:1069–73.PubMedCrossRef

37.

Nagel MA, Khmeleva N, Choe A, Gutierrez J, Gilden D. Varicella zoster virus (VZV) in cerebral arteries of subjects at high risk for VZV reactivation. J Neurol Sci. 2014;339:32–4.PubMedPubMedCentralCrossRef

38.

Nagel MA, Choe A, Khmeleva N, Overton L, Rempel A, Wyborny A, et al. Search for varicella zoster virus and herpes simplex virus-1 in normal human cerebral arteries. J Neurovirol. 2013;19:181–5.PubMedPubMedCentralCrossRef

39.••

Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer PJ, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015;84:1948–55. This pathological study looked for VZV antigen, virions and DNA in 82 temporal arteries from patients with biopsy-proven giant cell arteries, compared with 13 normal temporal arteries. VZV antigen was found in 74% of GCA-positive TAs, compared with 1/13 normal TAs (p < 0.0001, RR 9.67, 95%CI 1.46-63.69). The VZV was found mostly in skip areas adjacent to regions with GCA pathology.PubMedCrossRef

40.

Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis. 2014;58:1497–503.PubMedPubMedCentralCrossRef

41.

Kang J-H, Ho J-D, Chen Y-H, Lin H-C. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke. 2009;40:3443–8.PubMedCrossRef

42.

Lin H-C, Chien C-W, Ho J-D. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology. 2010;74:792–7.PubMedCrossRef

43.

Zepper P, Wunderlich S, Forschler A, Nadas K, Hemmer B, Sellner J. Pearls & Oy-sters: cerebral HSV-2 vasculitis presenting as hemorrhagic stroke followed by multifocal ischemia. Neurology. 2012;78:e12–5.PubMedCrossRef

44.

Guerrero WR, Dababneh H, Hedna S, Johnson JA, Peters K, Waters MF. Vessel wall enhancement in herpes simplex virus central nervous system vasculitis. J Clin Neurosci. 2013;20:1318–9.PubMedCrossRef

45.

Snider SB, Jacobs CS, Scripko PS, Klein JP, Lyons JL. Hemorrhagic and ischemic stroke secondary to herpes simplex virus type 2 meningitis and vasculopathy. J Neurovirol. 2014;20:419–22.PubMedCrossRef

46.

Terlizzi V, Improta F, Di Fraia T, Sanguigno E, D’Amico A, Buono S, et al. Primary herpes virus infection and ischemic stroke in childhood: a new association? J Clin Neurosci. 2014;21:1656–8.PubMedCrossRef

47.

Fullerton HJ, Elkind MSV, Glaser CA, Hills NK, Luna JM, Sear K, et al. Herpes viruses in childhood arterial ischemic stroke: interim results of the VIPS Study. Stroke. 2014;45:A38.CrossRef

48.

Mizusawa H, Hirano A, Llena JF, Shintaku M. Cerebrovascular lesions in acquired immune deficiency syndrome (AIDS). Acta Neuropathol. 1988;76:451–7.PubMedCrossRef

49.

Kieburtz KD, Eskin TA, Ketonen L, Tuite MJ. Opportunistic cerebral vasculopathy and stroke in patients with the acquired immunodeficiency syndrome. Arch Neurol. 1993;50:430–2.PubMedCrossRef

50.

Benjamin LA, Bryer A, Emsley HCA, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. The Lancet Neurology. 2012;11:878–90.PubMedPubMedCentralCrossRef

51.

Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology. 2011;76:444–50.PubMedPubMedCentralCrossRef

52.

Gutierrez J, Elkind MSV, Marshall RS. Cardiovascular profile and events of US adults 20–49 years with HIV: results from the NHANES 1999–2008. AIDS Care. 2013;25:1385–91.PubMedCrossRef

53.

Vinikoor MJ, Napravnik S, Floris-Moore M, Wilson S, Huang DY, Eron JJ. Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. AIDS Res Hum Retroviruses. 2013;29:1068–74.PubMedPubMedCentralCrossRef

54.

Mateen FJ, Post WS, Sacktor N, Abraham AG, Becker JT, Smith BR, et al. Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men. Neurology. 2013;81:2094–102.PubMedPubMedCentralCrossRef

55.

Krsak M, Kent DM, Terrin N, Holcroft C, Skinner SC, Wanke C. Myocardial infarction, stroke, and mortality in cART-treated HIV patients on statins. AIDS Patient Care STDS. 2015;29:307–13.PubMedCrossRef

56.•

Sico JJ, Chang C-CH, So-Armah K, Justice AC, Hylek E, Skanderson M, et al. HIV status and the risk of ischemic stroke among men. Neurology. 2015;84:1933–40. This study examined the incidence of ischemic stroke in a cohort of 76,835 male veterans free of baseline cardiovascular disease. Over a median follow-up period of 5.9 years, HIV-infected veterans had a higher stroke rate than matched uninfected veterans (incidence rate ratio 1.25, p < 0.01). The rate remained higher even after adjusting for comorbidities.PubMedCrossRef

57.•

Chow FC, He W, Bacchetti P, Regan S, Feske SK, Meigs JB, et al. Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. Neurology. 2014;83:1705–11. This retrospective cohort study used billing data to compare rates of ICH in HIV-infected and uninfected patients. The incidence of ICH was higher in the HIV-infected patients (unadjusted incidence rate ratio of 1.85, 95%CI 1.37-2.47, p < 0.001). In the multivariable model, the effect was more pronounced in young patients and in women.PubMedPubMedCentralCrossRef

58.

Womack JA, Chang C-CH, So-Armah KA, Alcorn C, Baker JV, Brown ST, et al. HIV infection and cardiovascular disease in women. J Am Heart Assoc. 2014;3:e001035.PubMedPubMedCentralCrossRef

59.

Thakur KT, Lyons JL, Smith BR, Shinohara RT, Mateen FJ. Stroke in HIV-infected African Americans: a retrospective cohort study. J Neurovirol. 2015.

60.

Sweeney EM, Thakur KT, Lyons JL, Smith BR, Willey JZ, Cervantes-Arslanian AM, et al. Outcomes of intravenous tissue plasminogen activator for acute ischaemic stroke in HIV-infected adults. Eur J Neurol. 2014;21:1394–9.PubMedCrossRef

61.

Chow FC, Bacchetti P, Kim AS, Price RW, Hsue PY. Effect of CD4+ cell count and viral suppression on risk of ischemic stroke in HIV infection. AIDS. 2014;28:2573–7.PubMedCrossRef

62.

Marcus JL, Leyden WA, Chao CR, Chow FC, Horberg MA, Hurley LB, et al. HIV infection and incidence of ischemic stroke. AIDS. 2014;28:1911–9.PubMedCrossRef

63.

Goldstein DA, Timpone J, Cupps TR. HIV-associated intracranial aneurysmal vasculopathy in adults. J Rheumatol. 2010;37:226–33.PubMedCrossRef

64.

Gutierrez J, Glenn M, Isaacson RS, Marr AD, Mash D, Petito C. Thinning of the arterial media layer as a possible preclinical stage in HIV vasculopathy: a pilot study. Stroke. 2012;43:1156–8.PubMedCrossRef

65.•

Gutierrez J, Elkind MSV, Petito C, Chung DY, Dwork AJ, Marshall RS. The contribution of HIV infection to intracranial arterial remodeling: a pilot study. Neuropathology. 2013;33:256–63. This pathological study examined a measure of arterial remodeling by comparing the ratio of arterial lumen diameter to wall thickness in 51 cerebral arteries from 5 HIV-infected and 13 uninfected brain donors. Arteries from HIV-infected donors had significantly higher ratios, suggesting an association of HIV infection with brain outward arterial remodeling.PubMedPubMedCentralCrossRef

66.

Gutierrez J, Rosoklija G, Murray J, Chon C, Elkind MSV, Goldman J, et al. A quantitative perspective to the study of brain arterial remodeling of donors with and without HIV in the Brain Arterial Remodeling Study (BARS). Front Physiol. 2014;5:56.PubMedPubMedCentral

67.••

Gutierrez J, Goldman J, Dwork AJ, Elkind MSV, Marshall RS, Morgello S. Brain arterial remodeling contribution to nonembolic brain infarcts in patients with HIV. Neurology. 2015;85:1–8. Expanding on prior work (see ref 65), this study examined 1,878 cerebral artery segments from 284 HIV-infected and uninfected brain donors. HIV infection was associated with two extremes of arterial remodeling: inward remodeling with accelerated cerebral atherosclerosis causing ischemic infarcts, and outward remodeling causing dolichoectasia and otherwise unexplained infarcts. The dolichoectatic subtype predominated in more immunosuppressed patients.CrossRef

68.

Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. 2009;48:1713–23.PubMedCrossRef

69.

Mandrioli J, Portolani M, Cortelli P, Sola P. Middle cerebral artery thrombosis in course of parvovirus B19 infection in a young adult: a new risk factor for stroke? J Neurovirol. 2004;10:71–4.PubMedCrossRef

70.

Isumi H, Nunoue T, Nishida A, Takashima S. Fetal brain infection with human parvovirus B19. Pediatr Neurol. 21:661–3.

71.

Luna JM, Fullerton HJ, Wintermark M, deVeber GA, Hills NK, Muhammad K, et al. Parvovirus B19 DNA prevalence is increased in pediatric stroke patients compared to controls: pilot findings from the Vascular Effects of Infection in Pediatric Stroke (VIPS) study. Stroke. 2014;45:A36.CrossRef

72.

Elkind MSV. Why now? Moving from stroke risk factors to stroke triggers. Curr Opin Neurol. 2007;20:51–7.PubMedCrossRef

73.

Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–8.PubMedCrossRef

74.

Elkind MSV, Carty CL, O’Meara ES, Lumley T, Lefkowitz D, Kronmal RA, et al. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke. 2011;42:1851–6.PubMedPubMedCentralCrossRef

75.

Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry. Tex Heart Inst J. 2004;31:28–32.PubMedPubMedCentral

76.

Grau AJ, Fischer B, Barth C, Ling P, Lichy C, Buggle F. Influenza vaccination is associated with a reduced risk of stroke. Stroke. 2005;36:1501–6.PubMedCrossRef

77.

Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol. 2006;48:1498–502.PubMedCrossRef

78.

Lin H-C, Chiu H-F, Ho S-C, Yang C-Y. Association of influenza vaccination and reduced risk of stroke hospitalization among the elderly: a population-based case–control study. Int J Environ Res Public Health. 2014;11:3639–49.PubMedPubMedCentralCrossRef

79.•

Lavallee PC, Labreuche J, Fox KM, Lavados P, Mattle H, Steg PG, et al. Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke. Neurology. 2014;82:1905–13. This meta-analysis pooled data from 2 prospective cohort studies and one randomized trial (total 23,110 patients) to examine whether influenza vaccination was associated with reduced risk of major vascular events in patients with recent TIA or ischemic stroke. After adjusting for baseline characteristics, influenza vaccination was not associated with a reduction in vascular event rate. Subgroup analysis similarly showed no reduction in stroke or MI separately.PubMedCrossRef

80.

Rahman B, Heywood A, Moa A, MacIntyre CR. Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke. Neurology. 2015;84:105.PubMedCrossRef

81.

Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A, Gomez F, et al. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up. BMC Public Health. 2012;12:222.PubMedPubMedCentralCrossRef

82.•

Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, de Diego C, Satue E. Ineffectiveness of pneumococcal vaccination in cardiovascular prevention: the CAPAMIS study. JAMA Intern Med. 2013;173:1918–20. This prospective cohort study followed 27,204 patients over age 60 in primary care practices in Spain, to assess the effect of pneumococcal vaccination on hospitalization for stroke, MI and community acquired pneumonia. At 3 year follow-up, there was no protective effect of vaccination on any of these measures, in contrast to interim analysis that had shown such an effect.PubMed

83.

Tseng HF, Slezak JM, Quinn VP, Sy LS, Van den Eeden SK, Jacobsen SJ. Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. JAMA. 2010;303:1699–706.PubMedCrossRef

84.

Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180:48–58.PubMedPubMedCentralCrossRef

85.

Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.PubMed

86.

Bloemenkamp DGM, Mali WPTM, Tanis BC, Rosendaal FR, van den Bosch MAAJ, Kemmeren JM, et al. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. Atherosclerosis. 2002;163:149–56.PubMedCrossRef

87.

Haider AW, Wilson PWF, Larson MG, Evans JC, Michelson EL, Wolf PA, et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol. 2002;40:1408–13.PubMedCrossRef

88.

Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107:251–7.PubMedCrossRef

89.

Khairy P, Rinfret S, Tardif J-C, Marchand R, Shapiro S, Brophy J, et al. Absence of association between infectious agents and endothelial function in healthy young men. Circulation. 2003;107:1966–71.PubMedCrossRef

90.

Muller BT, Huber R, Henrich B, Adams O, Berns G, Siebler M, et al. Chlamydia pneumoniae, herpes simplex virus and cytomegalovirus in symptomatic and asymptomatic high-grade internal carotid artery stenosis. Does infection influence plaque stability? Vasa. 2005;34:163–9.PubMedCrossRef

91.

Hagiwara N, Toyoda K, Inoue T, Shimada H, Ibayashi S, Iida M, et al. Lack of association between infectious burden and carotid atherosclerosis in Japanese patients. J Stroke Cerebrovasc Dis. 2007;16:145–52.PubMedCrossRef

92.

Rupprecht HJ, Blankenberg S, Bickel C, Rippin G, Hafner G, Prellwitz W, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001;104:25–31.PubMedCrossRef

93.

Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002;33:2581–6.PubMedCrossRef

94.

Elkind MSV, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, et al. Infectious burden and risk of stroke: the northern Manhattan study. Arch. Neurol. [Internet]. 2009;67:33–8. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19901154&retmode=ref&cmd=prlinks.

95.•

Katan M, Moon YP, Paik MC, Sacco RL, Wright CB, Elkind MSV. Infectious burden and cognitive function: the Northern Manhattan Study. Neurology. 2013;80:1209–15. A composite index of infectious burden was previously shown to be associated with stroke risk and atherosclerosis in this multi-ethnic urban cohort. In this study, the same measure was found to be associated with worse performance on cognitive assessments, even after adjusting for vascular risk factors. The measure was not associated with cognitive decline over time.PubMedPubMedCentralCrossRef

96.

Wright CB, Gardener H, Dong C, Yoshita M, DeCarli C, Sacco RL, et al. Infectious burden and cognitive decline in the northern Manhattan study. J Am Geriatr Soc. 2015;63:1540–5.PubMedCrossRef

97.

Bu X-L, Yao X-Q, Jiao S-S, Zeng F, Liu Y-H, Xiang Y, et al. A study on the association between infectious burden and Alzheimer’s disease. Eur J Neurol. 2014.

98.

O’Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290:1459–66.PubMedCrossRef

99.

Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637–45.PubMedCrossRef

100.

Westendorp WF, Nederkoorn PJ, Vermeij J-D, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol. 2011;11:110.PubMedPubMedCentralCrossRef

101.•

Lord AS, Langefeld CD, Sekar P, Moomaw CJ, Badjatia N, Vashkevich A, et al. Infection after intracerebral hemorrhage: risk factors and association with outcomes in the ethnic/racial variations of intracerebral hemorrhage study. Stroke. 2014;45:3535–42. This retrospective study of 800 patients with ICH found that post-ICH infections were more likely to occur in patients with larger and deeper hemorrhages, and in black patients. Patients with infections had higher discharge mortality (16% vs 8%, p=0.001) and worse 3-month functional outcomes.PubMedPubMedCentralCrossRef

102.

Emsley HCA, Smith CJ, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol. 2007;7:5.PubMedPubMedCentralCrossRef

103.

Chamorro A, Urra X, Planas AM. Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke. 2007;38:1097–103.PubMedCrossRef

104.•

Westendorp WF, Vermeij J-D, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJLW, et al. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. Lancet. 2015;385:1519–26. This PROBE-design trial randomly assigned 2550 patients in the first 24 hours after acute stroke admitted to stroke units to IV ceftriaxone for 4 days vs usual care. In the intention-to-treat analysis, antibiotic treatment did not improve functional outcomes at three months.PubMedCrossRef

105.

Zierath D, Kunze A, Fecteau L, Becker K. Effect of antibiotic class on stroke outcome. Stroke. 2015;46:2287–92.PubMedCrossRef

Titel: Infection and Stroke: an Update on Recent Progress
verfasst von: Eliza C. Miller
Mitchell S. V. Elkind
Publikationsdatum: 01.01.2016
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 1/2016
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-015-0602-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma

Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke

Advances in Biomarker Research in Parkinson’s Disease

Opportunistic Neurologic Infections in Patients with Acquired Immunodeficiency Syndrome (AIDS)

Understanding and Promoting Resiliency in Patients with Chronic Headache